JP2023539754A - Ｌｚｋ標的化分解剤および使用方法 - Google Patents

Ｌｚｋ標的化分解剤および使用方法 Download PDF

Info

Publication number
JP2023539754A
JP2023539754A JP2023513976A JP2023513976A JP2023539754A JP 2023539754 A JP2023539754 A JP 2023539754A JP 2023513976 A JP2023513976 A JP 2023513976A JP 2023513976 A JP2023513976 A JP 2023513976A JP 2023539754 A JP2023539754 A JP 2023539754A
Authority
JP
Japan
Prior art keywords
lzk
compound
substituted
unsubstituted
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023513976A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023539754A5 (enExample
Inventor
ジョン エフ． ブログナード，
ロルフ イー． スウェンソン，
エイミー エル． ファンク，
キャロリン ダブリュー． ヒトコ，
キャサリン エム． ナイスワーナー，
エリック リンドバーグ，
ベンカタレディ サバサニ，
ニコル エル． バーグマン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of JP2023539754A publication Critical patent/JP2023539754A/ja
Publication of JP2023539754A5 publication Critical patent/JP2023539754A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2023513976A 2020-09-02 2021-09-01 Ｌｚｋ標的化分解剤および使用方法 Pending JP2023539754A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063073835P 2020-09-02 2020-09-02
US63/073,835 2020-09-02
PCT/US2021/048600 WO2022051326A1 (en) 2020-09-02 2021-09-01 Lzk‑targeting degraders and methods of use

Publications (2)

Publication Number Publication Date
JP2023539754A true JP2023539754A (ja) 2023-09-19
JP2023539754A5 JP2023539754A5 (enExample) 2024-09-05

Family

ID=78087503

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023513976A Pending JP2023539754A (ja) 2020-09-02 2021-09-01 Ｌｚｋ標的化分解剤および使用方法

Country Status (6)

Country Link
US (1) US20240190838A1 (enExample)
EP (1) EP4208455A1 (enExample)
JP (1) JP2023539754A (enExample)
AU (1) AU2021336300A1 (enExample)
CA (1) CA3193736A1 (enExample)
WO (1) WO2022051326A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025188848A1 (en) * 2024-03-06 2025-09-12 Uereka Biosciences, Inc. Lzk inhibitors
CN118652241A (zh) * 2024-05-29 2024-09-17 浙江工业大学 mTOR蛋白靶向降解嵌合体及其制备方法与应用
WO2026024674A1 (en) 2024-07-22 2026-01-29 Genesis Therapeutics, Inc. Methods of treating skp2-associated cancers

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016169989A1 (en) * 2015-04-22 2016-10-27 Glaxosmithkline Intellectual Property Development Limited Iap e3 ligase directed proteolysis targeting chimeric molecules
JP2019528319A (ja) * 2016-08-29 2019-10-10 ボード オブ レジェンツ, ザ ユニバーシティ オブ テキサス システムBoard Of Regents, The University Of Texas System 疾患の処置のための二重ロイシンジッパー（ｄｌｋ）キナーゼの阻害薬
WO2019195609A2 (en) * 2018-04-04 2019-10-10 Arvinas Operations, Inc. Modulators of proteolysis and associated methods of use
JP2020502092A (ja) * 2016-12-08 2020-01-23 ボード オブ レジェンツ, ザ ユニバーシティ オブ テキサス システムBoard Of Regents, The University Of Texas System 疾患の治療のための二重ロイシンジッパー（ｄｌｋ）キナーゼのビシクロ［１．１．１］ペンタン阻害剤

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US10806737B2 (en) * 2016-12-23 2020-10-20 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of fetal liver kinase polypeptides
US11560366B2 (en) * 2019-10-21 2023-01-24 Board Of Regents, The University Of Texas System Bicyclo[1.1.1]pentane inhibitors of dual leucine zipper (DLK) kinase for the treatment of disease
WO2021141662A1 (en) * 2020-01-10 2021-07-15 Massachusetts Institute Of Technology Proteolysis targeting chimeric molecules (protacs) with functional handles and uses thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016169989A1 (en) * 2015-04-22 2016-10-27 Glaxosmithkline Intellectual Property Development Limited Iap e3 ligase directed proteolysis targeting chimeric molecules
JP2019528319A (ja) * 2016-08-29 2019-10-10 ボード オブ レジェンツ, ザ ユニバーシティ オブ テキサス システムBoard Of Regents, The University Of Texas System 疾患の処置のための二重ロイシンジッパー（ｄｌｋ）キナーゼの阻害薬
JP2020502092A (ja) * 2016-12-08 2020-01-23 ボード オブ レジェンツ, ザ ユニバーシティ オブ テキサス システムBoard Of Regents, The University Of Texas System 疾患の治療のための二重ロイシンジッパー（ｄｌｋ）キナーゼのビシクロ［１．１．１］ペンタン阻害剤
WO2019195609A2 (en) * 2018-04-04 2019-10-10 Arvinas Operations, Inc. Modulators of proteolysis and associated methods of use

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
ANGEW. CHEM. INT. ED., vol. 55, JPN6025028327, 2016, pages 1966 - 1973, ISSN: 0005817884 *
ANNU. REV. CELL DEV. BIOL., vol. 35, JPN6025028325, 2019, pages 501 - 521, ISSN: 0005817882 *
CELLULAR SIGNALLING, vol. Vol.63 (109366), JPN6025028326, 2019, pages 1 - 9, ISSN: 0005817883 *
J. MED. CHEM., vol. 58, JPN6025028323, 2015, pages 8182 - 8199, ISSN: 0005817880 *
J. MED. CHEM., vol. 58, JPN6025028324, 2015, pages 401 - 418, ISSN: 0005817881 *
J. MED. CHEM., vol. 61, JPN6025028322, 2018, pages 8078 - 8087, ISSN: 0005817879 *
J. MED. CHEM., vol. 61, JPN6025028329, 2018, pages 444 - 452, ISSN: 0005817886 *
NATURE REVIEWS DRUG DISCOVERY, vol. 16, JPN6025028328, 2017, pages 101 - 104, ISSN: 0005817885 *

Also Published As

Publication number Publication date
CA3193736A1 (en) 2022-03-10
AU2021336300A1 (en) 2023-03-16
WO2022051326A1 (en) 2022-03-10
EP4208455A1 (en) 2023-07-12
US20240190838A1 (en) 2024-06-13

Similar Documents

Publication Publication Date Title
US20240190838A1 (en) Lzk-targeting degraders and methods of use
US10954287B2 (en) Ras binding peptides and methods of use
KR20150093695A (ko) Malt1의 소분자 억제제
JP2019508404A (ja) 癌患者の層別化および癌治療のための化合物、組成物および方法
JP7850460B2 (ja) ヘテロ環式カリンｒｉｎｇユビキチンリガーゼ化合物及びその使用
CA3172987A1 (en) Small molecule inhibitors of oncogenic chd1l with preclinical activity against colorectal cancer
JP2018504441A (ja) 癌の治療に有用なｅｇｆｒ阻害剤としての新規フッ素化誘導体
US20250032489A1 (en) Mixed lineage kinase inhibitors and methods of use
JP2020105195A (ja) Ｒａｌ ＧＴＰアーゼを標的とする抗癌化合物及びそれを使用する方法
CN107531683A (zh) Usp7抑制剂化合物及使用方法
CN114127050A (zh) 适用于稳定化致淀粉样变免疫球蛋白轻链的苯并吡喃和咪唑衍生物
TW202202143A (zh) 使用cdk4/6及cdk2抑制劑共同治療以遏止腫瘤對cdk2抑制劑之適應性
US20150246946A1 (en) Peptides and methods for treating cancer
WO2023203174A1 (en) Heterocyclic cullin ring ubiquitin ligase compounds and uses thereof
Ge et al. Discovery of SY-589, a Highly Potent and Orally Bioavailable Polθ Helicase Inhibitor for the Treatment of HR-Deficient Tumors
Jeon et al. Selective CDK6 Degradation via the KLHDC2 E3 Ubiquitin Ligase
US20250304585A1 (en) Sulfamate based covalent ligand-directed release (coldr) compounds
Jones et al. Activity-Based Proteomics Discovery of Deubiquitinating Enzyme Inhibitors with Immunomodulatory Activity
WO2024249959A1 (en) Compositions reducing the expression or activity of c1 galt1 for treating ewing sarcoma
JP2020508969A (ja) オーロラａキナーゼ選択的阻害剤
WO2025151850A9 (en) Spirocycle acrylamides that stereo- and site-selectively degrade the transcriptional and dna-damage response protein ercc3
WO2026025042A1 (en) P53 targeting compounds and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240827

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240827

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250626

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250709

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251007

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251209

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260317